Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
New England Journal of Medicine · 12.09.2024 · 391 (10) · 899-912
DOI: 10.1056/nejmoa2404143 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.09.2024. Verfasst von Christie M Ballantyne und 11 weiteren Autor:innen. Beteiligte Einrichtung: From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Tr…. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hyperlipidemias, RNA, Small Interfering, Triglycerides. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Trials, Northridge (M.A.), Arrowhead Pharmaceuticals, Pasadena (T.C., S.…
Förderung
- Arrowhead Pharmaceuticals
Zitieren
APA
Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., Hellawell, J., & Gaudet, D. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391(10), 899-912. https://doi.org/10.1056/nejmoa2404143
Vancouver
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine. 2024;391(10):899-912. doi:10.1056/nejmoa2404143
BibTeX
@article{Ballantyne2024,
author = {Ballantyne, Christie M and Vasas, Szilard and Azizad, Masoud and Clifton, Peter and Rosenson, Robert S and Chang, Ting and Melquist, Stacey and Zhou, Rong and Mushin, Ma'an and Leeper, Nicholas J and Hellawell, Jennifer and Gaudet, Daniel},
title = {Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {10},
pages = {899--912},
doi = {10.1056/nejmoa2404143}
}
EUVIMED